Biotechnology - Oncology

Filter

Current filters:

Oncology

Popular Filters

1 to 25 of 557 results

Green Cross Neulapeg biosimilar approved in South Korea

28-08-2014

South Korea’s Green Cross says that the country’s Ministry of Food and Drug Safety has granted marketing…

AmgenAsia-PacificBiosimilarsBiotechnologyGreen CrossNeulapegNeulastaOncologyRegulation

Advaxis and Merck & Co collaborate on prostate cancer

Advaxis and Merck & Co collaborate on prostate cancer

26-08-2014

US cancer immunotherapies firm Advaxis has entered into a clinical trial collaboration agreement with…

AdvaxisADXS-PSABiotechnologyLicensingMerck & CoOncologypembrolizumabResearch

AstraZeneca to collaborate with Illumina on gene sequencing panel for diagnostic tests

AstraZeneca to collaborate with Illumina on gene sequencing panel for diagnostic tests

21-08-2014

Anglo-Swedish drug major AstraZeneca is to collaborate with gene sequencing company Illumina to develop…

AstraZenecaBiotechnologyGeneticsIlluminaOncologyPersonalized healthcareResearch

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

20-08-2014

US biopharmaceutical firm Emergent BioSolutions and Germany’s MorphoSys have entered into an agreement…

BiotechnologyEmergent BioSolutionsES414GermanyLicensingMOR209/ES414MorphoSysOncologyProstate cancerUSA

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

15-08-2014

USA-based Amgen initiated a voluntary recall on June 26 for nine packaged lots of anemia drug Aranesp…

AmgenAnemiaAranespBiotechnologyMarkets & MarketingOncologyRegulation

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

Amgen’s Kyprolis failed to meet primary endpoint in multiple myeloma trial

14-08-2014

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals,…

Advanced refractory multiple myelomaAmgenBiotechnologyKyprolisOncologyOnyx PharmaceuticalsResearchUSA

TNI BioTech and Hubei Qianjiang link up on cancer drug development

TNI BioTech and Hubei Qianjiang link up on cancer drug development

13-08-2014

US biotech firm TNI BioTech has signed a supplemental agreement with China’s Hubei Qianjiang Pharmaceutical…

BiotechnologyBusiness FinanceChinaHubeiLicensingOncologyQianjiang PharmaceuticalResearchTNI BioTechUSA

Oncothyreon acquires Alpine Biosciences

Oncothyreon acquires Alpine Biosciences

12-08-2014

US biotech firm Oncothyreon says that it has acquired Alpine Biosciences, of Seattle, Washington, a privately…

Alpine BiosciencesBiotechnologyBusiness FinanceImmunotherapyMedicineMergers & AcquisitionsOncologyOncothyreonRare diseasesUSA

3SBio enters patent license agreement with DiNonA for Leukotuximab

3SBio enters patent license agreement with DiNonA for Leukotuximab

08-08-2014

Chinese biotechnology company 3SBio has entered into an exclusive license with Korean DiNonA for the…

3SBioBiotechnologyChinaDiNonAKoreaLeukemiaLeukotuximabLymphocytic leukemiaManufacturingMarkets & MarketingOncology

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

05-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has awarded sole subsidised supply status in…

BiotechnologyErythropoiesis-stimulating agentserythropoietinJanssen-CilagJohnson & JohnsonNew ZealandOncologyPricing

EMA’s CHMP backs approval of two new treatment options for rare cancers

EMA’s CHMP backs approval of two new treatment options for rare cancers

26-07-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use, at its July meeting,…

BiotechnologyEuropeFinancialGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonOncologyRegulationZydelig

Taiho Pharma and Sumitomo Dainippon both invest in Remiges BioPharma Fund

25-07-2014

Japanese oncology-focussed drugmaker Taiho Pharmaceutical has said that it will be investing $30 million…

BiotechnologyDainippon Sumitomo PharmaFinancialJapanOncologyRemiges BioPharma FundTaiho Pharmaceutical

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

US FDA approves Gilead’s Zydelig for three types of blood cancers

US FDA approves Gilead’s Zydelig for three types of blood cancers

24-07-2014

The US Food and Drug Administration late yesterday approved Zydelig (idelalisib), a new drug from US…

BiotechnologyGilead SciencesidelalisibOncologyRegulationUSAZydelig

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

22-07-2014

Anglo-Swedish drug major AstraZeneca says that its global biologics research and development arm MedImmune…

AdvaxisADXS-HPVAstraZenecaBiotechnologyMedImmuneOncologyPapillomavirusResearchSweden

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

22-07-2014

Australian biotech company Regeneus has expanded its portfolio to include licensing of global rights…

AustraliaBiotechnologyFinancialOncologyOsteosarcomaRegeneusResearchSarcoma

1 to 25 of 557 results

Back to top